GO:0042826 histone deacetylase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042826 histone deacetylase binding is a molecular function defined as binding to histone deacetylase, the enzyme class that removes acetyl groups from histone lysines.
• Histone deacetylases (HDACs) are zinc-dependent or NAD+-dependent enzymes; their binding partners include transcription factors, corepressors, and structural proteins.
• Binding to HDACs is critical for chromatin remodeling, gene silencing, and regulation of cell proliferation, differentiation, and survival.
• Dysregulated HDAC binding contributes to cancer, neurodegeneration, and inflammatory diseases, making these interactions prime therapeutic targets.
• Key HDAC-binding proteins include SIN3A, NCOR1, NCOR2, REST, and MEF2, which recruit HDACs to specific genomic loci.
• CRISPR-based knockout, point mutation, and knock-in models enable precise dissection of HDAC-binding interfaces and their functional consequences.
Description
Histone deacetylase binding (GO:0042826) is a molecular function that describes the physical interaction between a protein and a histone deacetylase (HDAC) enzyme. HDACs catalyze the removal of acetyl groups from lysine residues on histone tails, leading to chromatin compaction and transcriptional repression. This binding event is fundamental to epigenetic regulation, as it determines where and when HDACs are recruited to specific genomic regions. Researchers study this term to understand how HDACs are targeted to chromatin, how their activity is modulated by protein partners, and how disruptions in these interactions contribute to disease. The binding of HDACs to regulatory proteins such as SIN3A, NCOR1, and REST is essential for normal development and tissue homeostasis. In cancer, aberrant HDAC binding can silence tumor suppressor genes, promoting oncogenesis. In neurodegeneration, altered HDAC binding may affect neuronal survival and plasticity. Thus, GO:0042826 represents a central node in epigenetic signaling and a promising target for therapeutic intervention.
histone deacetylase binding At A Glance
| GO ID | GO:0042826 |
|---|---|
| GO term | histone deacetylase binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to histone deacetylase enzymes, facilitating their recruitment to chromatin and modulation of deacetylation activity. |
| Definition source | QuickGO |
| Related enzymes | HDAC1-11 (zinc-dependent), SIRT1-7 (NAD+-dependent) |
| Cellular context | Nucleus, chromatin, transcription regulatory complexes |
What Is GO:0042826?
GO:0042826 histone deacetylase binding is defined as the selective and non-covalent interaction of a protein or molecular complex with a histone deacetylase enzyme. This binding event is a molecular function that enables the recruitment of HDACs to specific substrates or genomic loci, thereby modulating their catalytic activity and substrate specificity. The term encompasses interactions with both zinc-dependent HDACs (class I, II, IV) and NAD+-dependent sirtuins (class III), although the QuickGO definition does not specify subtypes. Binding partners can be transcription factors, corepressors, or structural proteins that tether HDACs to chromatin.
Why Is histone deacetylase binding Important in Cell Biology?
Histone deacetylase binding is a pivotal molecular function because it dictates the spatial and temporal recruitment of HDACs to chromatin, thereby controlling gene expression programs essential for cell fate decisions, proliferation, and stress responses. Dysregulation of these interactions is implicated in a wide range of pathologies, including cancer, neurodegenerative disorders, and immune dysfunction. Understanding the structural and kinetic basis of HDAC binding informs the design of selective HDAC inhibitors and targeted epigenetic therapies.
• Controls chromatin remodeling and gene silencing by recruiting HDACs to specific loci.
• Regulates cell cycle progression, differentiation, and apoptosis.
• Implicated in oncogenesis through silencing of tumor suppressor genes.
• Contributes to neurodegeneration by altering neuronal gene expression.
• Modulates immune responses and inflammation via HDAC-corepressor complexes.
• Target for HDAC inhibitors in cancer therapy and other diseases.
• Essential for developmental processes and tissue homeostasis.
• Provides a mechanism for signal-dependent epigenetic regulation.
Molecular Mechanism of histone deacetylase binding
Recognition and Recruitment of HDACs
In simple terms: Proteins that bind HDACs act like molecular hooks that grab the enzyme and bring it to the right place in the genome.
Histone deacetylase binding typically involves specific protein-protein interaction domains, such as the SIN3 interaction domain (SID) or the NCOR/SMRT deacetylase activation domain (DAD), which recognize conserved surfaces on HDACs. These interactions are often mediated by short linear motifs and can be regulated by post-translational modifications. For example, the corepressor NCOR1 binds HDAC3 via a DAD, forming a stable complex that is essential for its deacetylase activity. Similarly, the transcription factor REST recruits HDAC1/2 to neuronal gene promoters through a SIN3 adaptor. The binding event itself can induce conformational changes in the HDAC that enhance its catalytic efficiency or alter its substrate specificity.
Structural Basis of HDAC Binding
In simple terms: The shape and chemical properties of the HDAC surface determine which proteins can bind to it.
HDACs share a conserved catalytic domain with a zinc ion coordinated by histidine and aspartate residues. The binding interface for partner proteins often lies outside the active site, on the surface of the enzyme. For instance, molecular dynamics simulations of HDAC8 with the inhibitor PCI-34051 revealed that binding can induce long-range conformational changes that affect the active site. Similarly, macrocyclic octapeptides bind to HDAC6 at a site that overlaps with the substrate-binding groove, providing insights into how protein partners might compete with substrates. These studies highlight that HDAC binding is not a simple lock-and-key event but involves dynamic allosteric regulation.
Kinetics and Thermodynamics of Binding
In simple terms: How tightly and how fast a protein binds to HDAC can determine its biological effect.
The binding of proteins to HDACs can be characterized by kinetic and thermodynamic parameters such as dissociation constants (Kd) and residence times. Slow-binding inhibitors of HDACs, for example, exhibit long residence times that correlate with prolonged cellular effects. Metal-binding kinetics to HDAC8 have been studied using stopped-flow techniques, revealing that zinc binding is a two-step process with distinct conformational changes. These principles apply to protein-protein interactions as well: the affinity and kinetics of HDAC binding partners can modulate the duration and intensity of deacetylation signals.
Regulation of HDAC Binding by Cofactors and Modifications
In simple terms: Other molecules and chemical tags can change how well HDACs bind to their partners.
The interaction between HDACs and their binding partners can be regulated by cofactors such as NAD+ for sirtuins, or by post-translational modifications of either the HDAC or the partner protein. For example, phosphorylation of HDAC1 can alter its affinity for SIN3A. Additionally, the presence of zinc or other metal ions is critical for the structural integrity of zinc-dependent HDACs and their ability to bind partners. Small molecules that chelate zinc can disrupt HDAC binding and activity, as seen with phenolic compounds that act as HDAC inhibitors. Thus, the cellular context and metabolic state can fine-tune HDAC binding interactions.
Key Genes Involved in GO:0042826 histone deacetylase binding
The following genes encode proteins that are known to bind histone deacetylases, either as corepressors, transcription factors, or structural components of chromatin-modifying complexes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HDAC1 | Histone deacetylase; binds to SIN3A, NCOR, and other corepressors | Target for cancer therapy; model for studying deacetylation |
| HDAC2 | Histone deacetylase; component of SIN3 and NuRD complexes | Implicated in neuronal plasticity and cancer |
| HDAC3 | Histone deacetylase; requires NCOR1/SMRT for activity | Key regulator of metabolism and inflammation |
| HDAC6 | Cytoplasmic HDAC; binds to ubiquitinated proteins and dynein | Target for neurodegeneration and cancer |
| HDAC8 | Histone deacetylase; binds to structural proteins and inhibitors | Model for allosteric regulation and metal binding |
| SIN3A | Scaffold protein; recruits HDAC1/2 to transcription factors | Central to epigenetic silencing |
| NCOR1 | Nuclear receptor corepressor; activates HDAC3 | Regulates metabolism and differentiation |
| NCOR2 | Corepressor; forms complex with HDAC3 | Involved in development and cancer |
| REST | Transcription factor; recruits HDAC1/2 to neuronal genes | Critical for neurogenesis and neurodegeneration |
| MEF2 | Transcription factor; binds HDAC4/5/7 | Regulates muscle and neuronal differentiation |
| SIRT1 | NAD+-dependent deacetylase; binds to p53, FOXO | Metabolism, aging, and cancer |
| SIRT2 | NAD+-dependent deacetylase; binds to tubulin | Cell cycle and neurodegeneration |
| SIRT6 | NAD+-dependent deacetylase; binds to chromatin | DNA repair and aging |
| SIRT7 | NAD+-dependent deacetylase; binds to RNA polymerase I | Ribosome biogenesis and cancer |
| CHD4 | Component of NuRD complex; binds HDAC1/2 | Chromatin remodeling and cancer |
| MTA1 | Part of NuRD complex; interacts with HDAC1/2 | Metastasis and transcriptional repression |
| KDM1A | Lysine demethylase; binds HDAC1/2 in CoREST complex | Epigenetic regulation in cancer |
How Is histone deacetylase binding Regulated?
Histone deacetylase binding is regulated at multiple levels. Post-translational modifications such as phosphorylation, ubiquitination, and SUMOylation of either the HDAC or its binding partner can alter interaction affinity. For example, phosphorylation of HDAC1 by CK2 enhances its binding to SIN3A. Metabolic cues, such as NAD+ levels, regulate sirtuin binding to substrates. Additionally, the availability of zinc ions affects the stability and binding capability of zinc-dependent HDACs. Competitive binding by small molecules or other proteins can also modulate these interactions, as seen with HDAC inhibitors that occupy the active site and prevent substrate binding.
histone deacetylase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HDAC1 | Cancer (leukemia, breast cancer) | Knockout in cancer cell lines; xenograft models |
| HDAC2 | Alzheimer's disease, cancer | Neuronal-specific knockout mice; iPSC-derived neurons |
| HDAC3 | Inflammation, metabolic syndrome | Conditional knockout in macrophages; liver-specific KO |
| HDAC6 | Neurodegeneration, cancer | Knockout zebrafish; HDAC6 inhibitor treatment |
| SIRT1 | Aging, cancer, inflammation | SIRT1 knockout mice; overexpression models |
Cancer
Aberrant histone deacetylase binding is a hallmark of many cancers. For instance, the oncogenic fusion protein PML-RARα recruits HDACs to retinoic acid target genes, leading to differentiation block in acute promyelocytic leukemia. Overexpression of HDAC1 and HDAC2 is observed in various tumors and correlates with poor prognosis. HDAC inhibitors that disrupt these interactions have shown clinical efficacy in hematological malignancies. Furthermore, mutations in HDAC-binding partners such as NCOR1 can drive endocrine resistance in breast cancer.
Neurodegenerative Disorders
In Huntington's disease, mutant huntingtin binds to HDAC1 and HDAC3, altering their recruitment to neuronal genes and contributing to transcriptional dysregulation. Similarly, in Alzheimer's disease, HDAC2 binds to promoters of genes involved in synaptic plasticity, and its inhibition improves cognitive function in animal models. The interaction between REST and HDACs is also implicated in neuronal death and ischemia.
Inflammatory and Immune Diseases
HDAC3 binding to NCOR1 regulates the expression of inflammatory cytokines in macrophages. Disruption of this interaction leads to uncontrolled inflammation and is linked to sepsis and autoimmune diseases. SIRT1 binding to NF-κB modulates inflammatory responses, and its dysregulation is associated with chronic inflammation.
From histone deacetylase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HDAC1 binding to SIN3A affect gene silencing? | Point mutation in SIN3A SID domain using CRISPR |
| What is the effect of HDAC3 knockout on inflammatory gene expression? | Conditional knockout in macrophages |
| Can a disease-associated mutation in NCOR1 disrupt HDAC3 binding? | Knock-in of patient mutation in cell lines |
| How does HDAC6 binding to ubiquitin affect aggresome formation? | Overexpression of tagged HDAC6 in neurons |
| What is the role of SIRT1 binding to p53 in aging? | SIRT1 knockout and knock-in mouse models |
| Does HDAC8 allosteric regulation require specific binding partners? | CRISPR knockout of HDAC8 in cancer cells |
How to Study the histone deacetylase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interactions in cells | Detect endogenous HDAC complexes |
| GST pull-down | Direct binding between recombinant proteins | Map interaction domains |
| SPR | Binding kinetics (kon, koff, Kd) | Characterize HDAC-inhibitor interactions |
| ITC | Thermodynamics of binding | Measure affinity and enthalpy |
| Molecular dynamics | Conformational changes and binding modes | Study allosteric regulation |
| CRISPR knockout | Loss-of-function phenotypes | Identify genes required for HDAC binding |
| RNA-seq | Transcriptional changes | Assess impact of HDAC binding disruption |
| ChIP-seq | Genomic localization of HDACs | Map HDAC recruitment sites |
Co-Immunoprecipitation (Co-IP) and Pull-Down Assays
Co-IP is the gold standard for detecting histone deacetylase binding in cells. Cells are lysed, and HDACs or their binding partners are immunoprecipitated using specific antibodies. The presence of interacting proteins is then detected by Western blot or mass spectrometry. Pull-down assays using recombinant GST-tagged HDAC domains can map direct interactions.
Surface Plasmon Resonance (SPR) and Isothermal Titration Calorimetry (ITC)
These biophysical methods quantify the affinity and kinetics of HDAC binding. SPR measures real-time association and dissociation rates, while ITC provides thermodynamic parameters such as Kd, enthalpy, and entropy. They are used to validate binding interfaces and screen for inhibitors that disrupt interactions.
Molecular Dynamics Simulations
Computational simulations reveal the dynamic behavior of HDAC binding, including conformational changes and allosteric effects. For example, simulations of HDAC8 with PCI-34051 showed how binding at one site can affect distant regions. Docking studies of phenolic compounds with HDACs provide insights into binding modes.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes required for HDAC binding and function. For instance, knockout of HDAC1 or its partners can be combined with RNA-seq to assess transcriptional consequences. These screens are powerful for discovering novel regulators of HDAC recruitment.
How CRISPR Can Be Used to Study GO:0042826 histone deacetylase binding
Knockout
CRISPR knockout of HDAC genes or their binding partners is used to study loss-of-function phenotypes. For example, HDAC1 knockout in cancer cell lines reduces proliferation and alters gene expression. Knockout of SIN3A disrupts HDAC recruitment and leads to derepression of target genes. These models help establish causality between HDAC binding and cellular outcomes.
Point Mutation
CRISPR-mediated point mutations can disrupt specific binding interfaces without affecting overall protein stability. For instance, mutating the SID domain of SIN3A prevents HDAC1 binding, allowing researchers to dissect the functional consequences of that interaction. Similarly, point mutations in HDAC3 that abolish NCOR1 binding reveal the importance of this interaction for deacetylase activity.
Knock-in
Knock-in of tagged HDACs (e.g., GFP or HA) enables endogenous localization and interaction studies. CRISPR knock-in of a disease-associated mutation in NCOR1 can model its effect on HDAC3 binding and downstream gene expression. This approach preserves physiological regulation and provides more relevant insights than overexpression.
Overexpression
Overexpression of HDACs or their binding partners using CRISPR activation (CRISPRa) or lentiviral vectors can amplify binding signals for biochemical assays. For example, overexpression of HDAC6 in neurons enhances aggresome formation and protects against neurodegeneration. However, overexpression may cause artifacts, so results should be validated with endogenous models.
How EDITGENE Supports histone deacetylase binding Research
Researchers studying histone deacetylase binding-related genes often need to determine whether a candidate gene is causally involved in a specific epigenetic or disease process. This requires precise genetic models that can knockout, mutate, or tag the gene of interest without off-target effects. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such investigations, from single-gene knockout to genome-wide library screening.
Contact EDITGENE today to design your custom CRISPR model for histone deacetylase binding research.
Frequently Asked Questions About histone deacetylase binding
What is GO:0042826 histone deacetylase binding?
GO:0042826 is a Gene Ontology molecular function term that describes the binding of a protein to a histone deacetylase enzyme, enabling its recruitment to chromatin and modulation of deacetylation activity.
What genes are involved in histone deacetylase binding?
Key genes include HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, SIN3A, NCOR1, NCOR2, REST, MEF2, SIRT1-7, CHD4, MTA1, and KDM1A, among others.
How does histone deacetylase binding regulate gene expression?
Binding of HDACs to transcription factors and corepressors targets them to specific promoters, where they remove acetyl groups from histones, leading to chromatin compaction and transcriptional repression.
What diseases are associated with abnormal histone deacetylase binding?
Cancer, neurodegenerative disorders (e.g., Alzheimer's, Huntington's), and inflammatory diseases are linked to dysregulated HDAC binding.
What methods are used to study histone deacetylase binding?
Common methods include co-immunoprecipitation, GST pull-down, surface plasmon resonance, isothermal titration calorimetry, molecular dynamics simulations, and CRISPR-based genetic screens.
How can CRISPR be used to study histone deacetylase binding?
CRISPR can knockout HDACs or their binding partners, introduce point mutations to disrupt specific interfaces, knock in tags for localization studies, or overexpress proteins to amplify binding signals.
What are the therapeutic implications of targeting histone deacetylase binding?
Disrupting HDAC binding with small molecules or peptides can reactivate silenced genes and has shown promise in cancer therapy and neurodegeneration.
Which HDAC isoforms are most studied for binding interactions?
HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 are frequently studied due to their roles in cancer, neurodegeneration, and inflammation.
What is the role of zinc in histone deacetylase binding?
Zinc is essential for the catalytic activity and structural integrity of zinc-dependent HDACs; chelating zinc can disrupt HDAC binding and inhibit enzyme activity.
How does EDITGENE support research on histone deacetylase binding?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services to study HDAC binding and its downstream effects.
Conclusion
Histone deacetylase binding (GO:0042826) is a fundamental molecular function that governs epigenetic regulation by recruiting HDACs to specific genomic loci. Its dysregulation is implicated in cancer, neurodegeneration, and inflammatory diseases, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and biophysical techniques continue to unravel the structural and kinetic basis of these interactions. EDITGENE provides comprehensive tools to accelerate this research, from custom knockout cell lines to genome-wide screens.
References
- 1. Mukherjee A et al.. 2023. Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms.. J Med Chem 66(17):11672-11700 PMID: 37651268
- 2. Zhang L et al.. 2018. Zinc binding groups for histone deacetylase inhibitors.. J Enzyme Inhib Med Chem 33(1):714-721 PMID: 29616828
- 3. López-Rodas G et al.. 1993. Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin.. FEBS Lett 317(3):175-80 PMID: 8425601
- 4. Luo Y et al.. 2025. Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051.. Commun Biol 8(1):221 PMID: 39939814
- 5. Uba AI et al.. 2023. Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations.. Amino Acids 55(5):579-593 PMID: 36781452
- 6. Watson PR et al.. 2023. Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6.. ACS Chem Biol 18(4):959-968 PMID: 37027789
- 7. Cellupica E et al.. 2023. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.. J Biol Chem 299(1):102800 PMID: 36528061
- 8. Kim B et al.. 2015. Kinetics and thermodynamics of metal-binding to histone deacetylase 8.. Protein Sci 24(3):354-65 PMID: 25516458
